NBDF/ LinkedIn
Aug 31, 2025, 07:31
Avatrombopag Shows Promise for Pediatric Immune Thrombocytopenia in Late-Stage Global Trial: NBDF
National Bleeding Disorders Foundation shared on LinkedIn:
“Promising news for children and adolescents living with immune thrombocytopenia (ITP). A late-stage global trial shows avatrombopag, an oral treatment already approved for adults, can significantly improve platelet counts and reduce bleeding symptoms in pediatric patients, offering a potential new treatment option for an underserved population.
Learn more about the study results and what they could mean for pediatric ITP care in The Lancet Haematology.”
Stay updated with Hemostasis Today.
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:33Wilfried Dinh: Why Heart Patients Still Have Events Despite ”Optimal” Cardiovascular Therapy
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women